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KEY POINTS:  24	
• Hypertension is one of the most important and common complications in acromegaly, 25	
responsible to increased cardiovascular risk, higher rate of hospitalization and greater costs 26	
for the disease management. 27	
• The pathogenesis has not yet been fully elucidated and likely includes multiple factors.  28	
• A comprehensive, patient-centered approach, focusing not only on the biochemical control 29	
of acromegaly, but also on an early diagnosis of hypertension and a prompt anti-30	
hypertensive treatment, is required for optimal patient care. 31	
 32	
 33	
SYNOPSIS 34	
Hypertension is one of the most frequent complications in acromegaly, with a median frequency of 35	
33.6% (ranging from 11 to 54.7%). Although the pathogenesis has not been fully elucidated, it is 36	
probably the result of concomitant factors leading to expansion of extracellular fluid volume, 37	
increase of peripheral vascular resistances and development of sleep apnea syndrome. As the effect 38	
of normalization of GH and IGF1 excess on blood pressure levels is unclear, an early diagnosis of 39	
hypertension and prompt anti-hypertensive treatment are eagerly recommended, regardless of the 40	
specific treatment of the acromegalic disease and the level of biochemical control attained.   41	
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INTRODUCTION 42	
Acromegaly is a rare, chronic disease whose clinical manifestations are the consequence of GH and 43	
IGF1 excess that is usually caused by a GH-secreting pituitary adenoma 1. The disease is associated 44	
with a significant number of complications and comorbid conditions, mainly affecting the 45	
cardiovascular (CV) system 2. Arterial hypertension is among the most frequent CV complications 46	
of acromegaly; however, its role as a prognostic factor is not definitely established 3-7, despite the 47	
negative impact of hypertension on the acromegalic cardiomiopathy 8,9. The classic view that CV 48	
disease is the main culprit for the excess mortality in acromegalic patients 2,4 has been revisited in 49	
more recent studies 6,10,11. Nevertheless, CV disease is associated with an important disease burden, 50	
and significantly increases the rate of hospitalization and the health care costs 12. 51	
 52	
PREVALENCE AND CHARACTERISTICS 53	
The frequency of hypertension in acromegaly varies from 11% to 54.7%, averaging 33.6%, as 54	
reported in Table 1 that includes the main studies published in the last 15 years 3,4,6 13-23. The 55	
variability found in the prevalence of hypertension could be attributed to the different diagnostic 56	
criteria adopted over different periods of recruitment, and to population-related risk factors (genetic 57	
and racial differences, prevalence of obesity, unhealthy life style, such as smoking and excessive 58	
sodium or alcohol intake). It is worth of note that all these studies were retrospective and reported 59	
only on office measurements of blood pressure (BP), likely overestimating the actual frequency of 60	
hypertension compared with the ambulatory blood pressure monitoring (ABPM).  61	
This caveat was first demonstrated by Minniti et al. 24, who reported a frequency of 42.5% of 62	
hypertension in acromegalic patients with office BP measurements versus a frequency of 17.5% 63	
with ABPM. Similar findings were recently found by Costenaro et al. 25, who demonstrated a rate of 64	
23% hypertension with ABPM versus 32% with clinical measurements. Interestingly, they reported 65	
that BP levels recorded by ABPM were correlated with GH and IGF1 concentrations.  66	
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The correlation between severity of hypertension and GH, or IGF1 levels, has been investigated in 67	
several studies, but findings are discordant 6,26,27. A recent paper tried to dissect the problem, 68	
showing a positive correlation between BP levels and IGF1 concentrations when the latter were 69	
above the upper limit of normalcy, with an inverse relationship when IGF1 levels were within the 70	
normal range 28. The analysis included several studies, most of which have been carried out in non-71	
acromegalic patients, and supports a direct relationship in states characterized by overtly elevated 72	
IGF1, like uncontrolled acromegaly. In addition, it is plausible that other variables are important 73	
determinants of hypertension in acromegaly, such as the duration of disease 27, 29, patient age and 74	
body mass index, while family history of hypertension or gender have a more controversial role 19, 75	
27, 30. 76	
Hypertension in acromegalic patients is generally regarded as a mild disease that can be easily 77	
managed with standard antihypertensive drugs 31. A peculiar pattern of acromegaly-associated 78	
hypertension may be found in higher diastolic BP and lower systolic BP levels compared to non-79	
acromegalic hypertensive subjects 27, 32. Furthermore, studies using ABPM found a higher 80	
prevalence of non-dippers (almost 50%) in acromegalic hypertensive patients compared with 81	
patients with primary hypertension 32, 33. The non-dipping pattern is shared with other types of 82	
secondary hypertension and is associated with increased CV morbidity and mortality. 83	
 84	
 85	
PATHOGENESIS 86	
The pathogenesis of hypertension in acromegaly has not been yet fully clarified, but a multifactorial 87	
origin is the most convincing explanation (Figure 1). The development of hypertension may be 88	
attributable to a combined effect of a chronic GH/IGF1 excess on different systems that finally 89	
causes expansion of extracellular fluid volume, increase of peripheral vascular resistances, and 90	
development of the sleep apnea syndrome. 91	
 92	
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EXPANSION OF EXTRACELLULAR FLUID VOLUME 93	
The increase of total extracellular fluid volume is secondary to sodium and water retention by the 94	
kidney, due to direct and indirect effects of GH/IGF1 34. 95	
 96	
a) Direct GH anti-natriuretic effects 97	
The hypothesis of a GH direct effect fits well with the demonstration of GH receptors in human 98	
adrenal cortex 35. In rat models of acromegaly, GH had an aldosterone-independent anti-natriuretic 99	
effect, mediated through the epithelial Na+ channels (ENaC) of collecting ducts 36. The rats received 100	
furosemide, an antidiuretic drug able to inhibit the sodium reabsorption NCCK2 channels in the 101	
loop of Henle, and amiloride, which blocks the ENaC channels in the collecting ducts. In 102	
acromegalic rats, the furosemide-induced natriuresis was lower compared to controls, whereas the 103	
amiloride-induced natriuresis was higher, confirming the hypothesis that GH stimulates sodium 104	
transport in the distal nephron via ENaC channels. The increased activity of ENaC channels in 105	
acromegaly was demonstrated also in humans, using a similar model of pharmacological challenge 106	
with amiloride and furosemide 37. 107	
 108	
b) Effects of GH on the renin-angiotensin-aldosterone system 109	
The relationship between the renin-angiotensin-aldosterone system (RAAS) and GH/IGF1 excess 110	
has been carefully evaluated in the last decades, but remains controversial. The leading hypothesis 111	
is that increased aldosterone levels, directly stimulated by GH excess, contribute to hypertension in 112	
acromegaly without stimulation of plasma renin activity (PRA) 38. As matter of fact, no change has 113	
been found in RAAS activity during IGF1 administration 39 and low levels of PRA have been 114	
consistently detected in acromegalic patients 40, 41.  115	
A significant direct correlation between GH and aldosterone values in acromegalic patients has 116	
been observed and serum aldosterone concentration significantly decreased after normalization of 117	
GH secretion due to surgical cure, whereas renin concentrations remained unaffected. In animal 118	
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models, the association of chronic GH excess with increased aldosterone was independent of renin, 119	
IGF-I, or adrenal aldosterone synthase expression 38. On the contrary, a study concerning the 120	
polymorphisms of genes involved in the RAAS has underlined the role of aldosterone synthase 121	
(CYP11B2), showing that acromegalic patients with the CYP11B2 - 344CC genotype were affected 122	
by hypertension more frequently than patients with the CT/TT genotypes, with a significant 123	
increase of systolic BP 42. Conversely, no significant effect of polymorphisms in other genes, such 124	
as angiotensinogen (AGT) or angiotensin-converting enzyme (ACE), was reported in agreement 125	
with the findings of a more recent study 43.  126	
 127	
c) IGF1-mediated inhibition of ANP 128	
Some studies showed a reduction of atrial natriuretic peptide (ANP) secretion in acromegalic 129	
patients. McKnight and colleagues 44 compared plasma ANP levels of patients with active 130	
acromegaly versus healthy subjects, before and after a 4-h intravenous infusion of normal saline. 131	
ANP levels rose significantly in the control group, whereas in acromegalic patients they did not 132	
respond to saline stimulation. Although the basal ANP values were similar between the two groups, 133	
the 4-h ANP levels were significantly higher in the group of healthy subjects than in the 134	
acromegalic group. A few years later, Moller et al. 39 demonstrated that the inhibition of ANP-135	
induced natriuresis is mediated by IGF-I. 136	
 137	
d) Insulin mediated effect 138	
It is well known that acromegaly is often associated with insulin resistance and hyperinsulinemia. 139	
The anti-natriuretic effect of insulin has long been debated, but an action on renal sodium 140	
absorption has confirmed 45.  Although experimental studies in acromegalic patients are not 141	
available, the pathophysiological role of insulin-mediated changes in sodium balance fits well with 142	
the finding of higher insulin levels after oral glucose tolerance load in hypertensive than 143	
normotensives acromegalic patients 46, and higher BP levels in hyperinsulinemic acromegalic 144	
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patients 47. On the other hand, other studies did not find a difference in fasting or post-load plasma 145	
insulin values between hypertensive and normotensives acromegalic patients 48, 49, suggesting that 146	
other factors could be involved in the pathogenesis, such as the insulin-mediated activation of the 147	
sympathetic nervous system 50, 51. 148	
 149	
e) Sympathetic nervous system mediated effect 150	
The influence of the sympathetic nervous system on tubular processing of sodium is well known 51. 151	
On the contrary, controversial data on the role of an impaired sympathetic tone in acromegaly have 152	
been reported in the last decades 50. In this area of debate, the assessment of the 24-hour profiles of 153	
plasma catecholamine levels and BP in 14 acromegalic patients (before and after pituitary surgery) 154	
and 8 healthy controls demonstrated a flattened 24-hour profile of norepinephrine and BP in 155	
acromegalic patients, while the circadian norepinephrine rhythm was restored after surgery with 156	
normalization/reduction of GH/IGF-I levels 52. 157	
 158	
INCREASE OF PERIPHERAL VASCULAR RESISTANCES 159	
The effect of chronic GH and IGF-I excess on vascular resistances could explain the more apparent 160	
increase of diastolic versus systolic BP in acromegalic patients 27, 32. Recently, a study assessed with 161	
renal ultrasonography 57 acromegalic patients and showed that the Renal Resistive Index (RRI) was 162	
higher in 16 hypertensive acromegalic patients compared to 49 normotensive patients 53. Moreover, 163	
the RRI value was independently related to the presence of hypertension and correlated with IGF-1 164	
levels, supporting the hypothesis of a link between the severity of acromegaly and hypertension. 165	
 166	
a) Stimulation of vascular RAAS and vascular hypertrophy 167	
It has been demonstrated in vitro that both IGF1 and insulin were able to stimulate angiotensinogen 168	
production in cultures of vascular smooth muscle cells 54. Interestingly, the same study showed the 169	
role of the two hormones in the development of vascular hypertrophy, through activation of the 170	
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vascular RAAS. It is conceivable that the same mechanism could play a role in the pathogenesis of 171	
hypertension in acromegaly, according to studies that demonstrated an association between 172	
hyperinsulinemia and hypertension in this group of patients 46, 47. This hypothesis suits well with 173	
evidence of a hypertrophic remodeling of subcutaneous small resistance arteries in acromegalic 174	
patients compared with the eutrophic remodeling in patients with essential hypertension 55. The 175	
assessment of the structure of small arteries in biopsies of subcutaneous fat and of the calculated 176	
media-to-lumen ratio and growth indices demonstrated the effect of growth factors in the 177	
development of vascular morphological alterations. A weak, but statistically significant correlation 178	
between the media-to-lumen ratio and IGF-1 values was also found in this small group of 9 179	
acromegalic patients. Similar findings on vascular hypertrophy in acromegaly, and a positive 180	
association between wall thickness and IGF-I levels, have been showed in a subsequent study 181	
including a larger sample of 41 patients 56. 182	
 183	
b) Endothelial dysfunction 184	
The comparison of the cutaneous vasoreactivity responses of 10 normotensive acromegalic patients 185	
with 10 healthy controls demonstrated in the former group an impaired endothelium-dependent 186	
vasodilatation, which is mediated by nitric oxide (NO) 57. The NO pathway has been subsequently 187	
evaluated, also taking in consideration its effects on vascular resistance, platelet aggregation and 188	
inhibition of smooth muscle cell proliferation. A few years later, it was demonstrated a decrease of 189	
NO concentrations in acromegalic patients, due to a reduced endothelial NO synthase expression, 190	
and an inverse correlation between NO and GH/IGF-1 levels, and duration of acromegaly 58. 191	
Several recent studies confirmed the impairment of flow-mediated vasodilation 59, 60 and the role of 192	
reduced NO levels in acromegaly 56, 61, which may contribute to both hypertension and erectile 193	
dysfunction in male acromegalic patients 62. Finally, it deserves to be mentioned also the 194	
association between endothelial dysfunction and insulin resistance 63, as a further possible 195	
mechanism in this complex scenario. 196	
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 197	
c) Sympathetic activation 198	
The evidence of an over-reactivity to sympathetic stimulation in acromegaly has been provided 199	
using a cold pressor test to study sympathetic vasoreactivity 57. The study showed a significantly 200	
more pronounced increase in systolic BP, and a trend to a greater decrease in skin perfusion, in 201	
acromegalic patients compared with healthy control, with a greater, although not statistically 202	
significant, vasoconstriction in acromegaly. On the other hand, there are few and contradictory data 203	
on catecholamine levels without any clear evidence of increased sympathetic tone in acromegalic 204	
patients 50. A study comparing acromegalic patients and hypertensive control reported a 24-hour 205	
catecholamine secretion that was quantitatively similar, but without any circadian rhythm and a 206	
normal fall during the night in acromegalic patients 52. This is in agreement with other findings 207	
indicating a reduced nocturnal fall in BP in both normotensive and hypertensive acromegalic 208	
patients, with a prevalence of the “non-dipper” profile (mean nocturnal BP ≤10% of the average 209	
daytime BP) 32, 64. 210	
 211	
SLEEP APNEA 212	
Sleep apnea syndrome (SAS) is common in acromegaly, mainly due to anatomical changes in the 213	
entire respiratory system 29. Particularly, alterations of the bone and soft tissues in the craniofacial 214	
region (mandibular prognathism due to growth effect of GH/IGF1, macroglossia, pharyngeal and 215	
laryngeal swelling due to sodium and water retention) reduce the airflow during sleep, causing 216	
repeated hypoxic and hypercapnic episodes 65.  Therefore, the prevalence of SAS in active 217	
acromegaly is up to 45-80% of patients, according to different studies 66. As in the general 218	
population, SAS is independently associated with hypertension and cardiovascular disease 67, 68, and 219	
the role of SAS in the pathogenesis of hypertension in acromegaly should not be overlooked due to 220	
its contribution to the flattening of the nocturnal BP fall. 221	
 222	
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DIAGNOSIS AND MANAGEMENT 223	
A recent consensus on the diagnosis and treatment of acromegaly complications 31 recommended an 224	
early diagnosis and aggressive treatment of high BP levels, regardless of the specific treatment of 225	
acromegaly. Therefore, BP measurement is always recommended at diagnosis of acromegaly, but it 226	
must be reassessed during the long-term follow-up (every 6 months, or when acromegaly treatment 227	
is changed, if hypertensive) 31. It could be argued that the sole use of office measurements can lead 228	
to an overestimation of the frequency of hypertension 24, 25, but this risk could be minimized using a 229	
self-measurement pressure diary or AMBP.  230	
The choice of the antihypertensive agents, mainly angiotensin converting enzyme inhibitors 231	
[ACEi], angiotensin II receptor blockers [ARBs], thiazide-type diuretics, calcium channel blockers, 232	
does not significantly differ from the non-acromegalic patients and there is no recommendation on a 233	
preferential class of drugs 31, although recent researches have suggested that amiloride is a 234	
potentially interesting option 36, 37. Moreover, a recent study including a small number of 235	
acromegalic patients has demonstrated with cardiac magnetic resonance that cardiac indices were 236	
improved in the hypertensive subjects on ACEi or ARBs compared with other antihypertensive 237	
drugs 69. Given that sleep apnea exacerbates hypertension 68, its effective management is mandatory 238	
to improve BP control.  239	
 240	
 241	
EFFECT OF ACROMEGALY CONTROL 242	
The effect of attaining control of GH and IGF1 excess on BP levels was heterogeneous across 243	
studies. In 2008, a study showed significantly lower systolic and diastolic BP levels in 76 244	
acromegalic patients achieving disease control after 36 months, comparing with the remaining 29 245	
uncontrolled patients. Moreover, increased doses, and/or greater number of antihypertensive drugs, 246	
were needed in patients with uncontrolled disease 70. In addition, the biochemical control of 247	
acromegaly seems to have beneficial effects on BP levels also in non-hypertensive patients, 248	
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preventing the progression towards hypertension 33. A recent study, including 121 acromegalic 249	
patients (of whom 79 achieving biochemical control during follow-up), confirmed that hypertension 250	
was more frequent in uncontrolled acromegaly 20. 251	
However, some recently published articles downplayed the role of acromegaly control on BP levels. 252	
A study including 552 acromegalic patients, stratified according to disease activity at the last visit, 253	
demonstrated that the prevalence of hypertension was not modified by the successful treatment of 254	
acromegaly 71. Previously, a research including 200 acromegalic patients did not demonstrated at 255	
multivariate analysis that the lack of biochemical control was a predictor of hypertension, although 256	
the univariate analysis showed a six-fold higher risk of hypertension in uncontrolled patients 257	
compared with patients in remission after surgery 30. Although the question is still open, we 258	
reviewed a selection of papers addressing this issue that have been classified according to the 259	
treatment approach (Table 2). 260	
 261	
SURGERY 262	
The surgical removal of a GH-secreting adenoma, in most cases using a transsphenoidal approach, 263	
still represents the mainstay of treatment and a potentially rapid curative option 72. Several studies 264	
have investigated the impact of neurosurgery on BP levels and reported contrasting findings, 265	
probably due to different sample sizes, type of measurements (clinical measurements versus 266	
ABPM), BP cut-offs used, and timing of assessment after surgery. Studies showed a significant 267	
lowering of both clinical systolic and diastolic BP at 3 73 and 6 months after surgery 74. The first 268	
study used only office BP measurement, whereas ABPM was also performed in the second study 269	
showing a significant postoperative decrease of the 24-h diurnal and nocturnal systolic BP profile 270	
with no change in the diastolic profile. Moreover, a circadian rhythm of BP was restored in most of 271	
the patients with a blunted preoperative BP profile. Similarly, Minniti and colleagues 75, using both 272	
clinical measurement and ABPM before and 6 months after surgery, demonstrated a significant 273	
decrease of the clinical and 24-h systolic BP in 15 well-controlled patients after surgery, in contrast 274	
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with no change in 15 poorly controlled acromegalic subjects. In the first group, a normal BP 275	
circadian rhythm was restored in almost all patients, whereas no changes occurred in the second 276	
group. The reduction in systolic, but not diastolic BP, 6 months after surgery was confirmed by 277	
Reyes-Vidal and colleagues 76; in addition, a lowered diastolic BP was found 1 year after surgery. 278	
Colao and colleagues 77, comparing 56 acromegalic patients controlled with SSA and 33 cured with 279	
surgery, reported at 1 year a significant lowering of diastolic (but not systolic) BP in both groups. 280	
Interestingly, the effect of a long-term effect of remission on diastolic BP was confirmed by a study 281	
reporting that after a mean period from surgery of 12.7 years diastolic (but not systolic) BP was 282	
significantly lower in patients in remission than in patients with active acromegaly 78.  283	
 284	
SOMATOSTATIN ANALOGUES 285	
Although surgery is the treatment of choice, SSA (octreotide and lanreotide and the second-286	
generation multireceptor-targeted pasireotide) are the first-line medical therapy, with a proved 287	
efficacy in more than 50% of patients, and being able to improve significantly acromegalic 288	
comorbidities 79, 80. A retrospective study comparing 36 acromegalics treated with SSA and 33 sex-, 289	
age-, and BMI-matched patients cured after surgery, did not find any significant difference in 290	
diastolic and systolic BP between the two groups 81. Previously, a prospective study showed a 291	
significant reduction of systolic and diastolic BP in 36 acromegalic patients treated for 12-24-292	
months with depot long-acting octreotide 82. In 2007, however, a metanalysis demonstrated that 293	
SSA therapy did not lead to a clear fall in BP, suggesting a pressure-independent effect of SSA on 294	
heart 83. In 2009, a study evaluated the efficacy of 5 years of depot SSA as first-line therapy in 295	
acromegaly and demonstrated a reduction in BP and a reduction in the rate of hypertension 84. 296	
 297	
PEGVISOMANT 298	
The second-line medical therapy consists of Pegvisomant (PEG), an antagonist of the GH receptor 299	
able to normalize IGF-1 levels in 60-90% of patients 85-88 and recently indicated as potentially 300	
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responsible of permanent remission in selected patients with SSA-resistant acromegaly 89. However, 301	
data on its impact on BP levels are limited to small size studies and are conflicting. 302	
A prospective study including 16 patients with SSA-resistant acromegaly treated with PEG 303	
demonstrated no change in systolic and diastolic BP overall; however, a significant decrease of 304	
diastolic BP was apparent in the 4 hypertensive patients evaluated separately 90. Interestingly, 305	
whereas a 6-month therapy with PEG in 17 acromegalic patients did not significantly change 306	
systolic and diastolic BP 91, a 18-months therapy with PEG in 10 acromegalic patients significantly 307	
lowered systolic BP in the entire group, as well as in the group of hypertensive patients, but 308	
decreased diastolic BP only in the hypertensive patients 92. A recent prospective study of the same 309	
group, including 50 acromegalic patients assessed at baseline, after long-term treatment with SSA 310	
and after 12 and 60 months of combined treatment with SSA and PEG, demonstrated only a slight 311	
but non-significant improvement of systolic and diastolic BP after combined treatment compared 312	
with long-term SSA therapy 93. In 2010, Berg and colleagues 94 assessed BP levels at baseline and 313	
after 12 months of PEG therapy in 62 acromegalic patients, of which 42 had normalized IGF-I 314	
(controlled patients) and 20 had reduced, but not normalized IGF1 (partially controlled patients). 315	
Systolic BP was significantly lower in the former than in the latter group, and decreased 316	
significantly during treatment only in controlled patients, but not in partially controlled patients. 317	
Diastolic BP was significantly lower in controlled than in partially controlled patients, but without 318	
significant changes in each group compared with baseline 94. More recently, a retrospective study 319	
including 96 patients treated with different modalities (surgery, SSA or PEG) reported a significant 320	
reduction, among the 11 patients who were hypertensive at diagnosis and whose antihypertensive 321	
treatment was not modified, in systolic BP after surgery, but not after PEG treatment, regardless of 322	
IGF1 changes 95. 323	
 324	
CABERGOLINE 325	
Cabergoline is a dopamine agonist, used in acromegaly as an adjuvant treatment as monotherapy in 326	
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patients with mild disease or in combination with SSA 72. To date, no prospective randomized trial 327	
evaluating its efficacy in acromegaly is available and no study reporting its effect on hypertension 328	
in acromegalic patients has been carried out. 329	
 330	
RADIOTHERAPY 331	
Radiotherapy is currently considered as a third-line option, in acromegalic patients uncontrolled 332	
after surgery and medical therapy, or in case of aggressive GH-secreting tumors 72. To our 333	
knowledge, no data focusing on the effect of radiotherapy on hypertension in acromegalic patients 334	
has been reported.  335	
  336	
CONCLUSION 337	
Hypertension is one of the most important and common complications in acromegaly. Its 338	
pathogenesis has not yet been fully elucidated, and likely includes multiple factors. A 339	
comprehensive, patient-centered approach, focusing not only on the biochemical control of 340	
acromegaly, but also on an early diagnosis of hypertension and a prompt anti-hypertensive 341	
treatment, is required for optimal patient care. However, there is an urgent need of prospective, 342	
large-scale studies focusing on hypertension, and its response to treatment of acromegaly, to solve 343	
the conundrum whether control of GH-IGF1 excess ameliorates BP levels.  344	
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Table 1 – Frequency of hypertension (HTN) in acromegaly in studies published over the last 15 years 579	
[national or local registries of acromegalic patients]. 580	
Country No of  
patients* 
No of HTN 
patients 
% of HTN 
patients# 
Mean 
age 
Study 
period 
Year of 
publication 
References 
Spain 1036 405 39.1 45.0 1997 − 2003 2004 [3] 
New Zealand 126 69 54.7 42.0 1964 − 2000 2004 [4] 
Belgium 409 161 39.4 44.0 2000 − 2004 2007 [13] 
Greece 84 - 46.0 47.0 1980 − 2009 2011 [14] 
Italy 1512 - 33.0 45.0 1980 − 2002 2012 [6] 
Malta 47 22 46.8 43.4 1979 − 2008 2012 [15] 
Canada 537 198 36.9 45.0 1980 − 2010 2013 [16] 
Iceland 52 25 48.1 44.5  1955 − 2013 2015 [17] 
Denmark 405 44 11.0 48.7 1991 − 2010 2016 [18] 
Mexico 2057 - 27.0 41.0 2009 − - - - -  2016 [19] 
USA 120 57 47.5 55.4 1985 − 2013 2017 [20] 
Sweden 358 142 39.7 50.0 2005 − 2013 2017 [21] 
Germany 479 186 45.5 45.7 - - - - − 2016 2017 [22] 
France 947 - 33.0 46.0 1999 − 2012 2017 [23] 
Weighted mean 
Range 
 33.6 
11.0-54.7 
    
*if specified, only patients with known information about hypertension; 581	
#if specified, data at diagnosis. 582	
 583	
 584	
 585	
 586	
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Table 2 – Effects of different treatments of acromegaly on hypertension. 588	
TREATMENT EFFECT ON HTN REFERENCES 
Surgery Amelioration of HTN with 
conflicting data on a more 
prominent effect on SBP vs. DBP 
[73-78] 
Somatostatin analogues Possible amelioration of HTN 
with long-term control of 
acromegaly 
[81-84] 
Pegvisomant Amelioration of HTN with long-
term control of acromegaly 
[90-95] 
Cabergoline NA – 
Radiotherapy NA – 
Abbreviations are as follows: HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic 589	
blood pressure; NA, not available 590	
 591	
 592	
FIGURE LEGEND 593	
 594	
Fig 1. Pathogenesis of hypertension in acromegaly. 595	
